Evaluation of the National Cholesterol Education Program Adult Treatment Panel III Algorithm for Selecting Candidates for Statin Therapy: Insights from the A to Z Trial

James A de Lemos, Stephen D. Wiviott, Sabina A. Murphy, Michael A. Blazing, Eldrin F. Lewis, Robert M. Califf, Marc A. Pfeffer, Eugene Braunwald

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The National Cholesterol Education Program Adult Treatment Panel III recommends an algorithm to integrate iterative risk-stratification information with low-density lipoprotein (LDL) cholesterol levels to identify candidates for statin therapy. We used the Aggrastat to Zocor (A to Z) trial, in which all patients presented with an acute coronary syndrome (ACS) event in the absence of previous statin therapy, to evaluate the performance of this algorithm. Of 1,750 patients with ACS included in this analysis, 1,126 (64%) had an indication for statin therapy before enrollment and 624 (36%) did not have a statin indication before enrollment. We estimate that initiating statin therapy at moderate dosages (decreasing LDL by 1 mmol/L) according to the National Cholesterol Education Program Adult Treatment Panel III guidelines would have prevented approximately 15% of the ACS events leading to enrollment in the A to Z trial, whereas more intensive statin therapy (decreasing LDL by 1.5 mmol/L) would have prevented >21% of events. Aspirin use before enrollment was reported in only 38% of subjects with a statin indication. In conclusion, these observations represent missed opportunities for primary and secondary prevention and highlight the need for assessment of patient risk and better adherence to existing prevention guidelines.

Original languageEnglish (US)
Pages (from-to)739-742
Number of pages4
JournalAmerican Journal of Cardiology
Volume98
Issue number6
DOIs
StatePublished - Sep 8 2006

Fingerprint

tirofiban
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin
Cholesterol
Education
Acute Coronary Syndrome
LDL Lipoproteins
Therapeutics
Guidelines
Needs Assessment
Primary Prevention
Secondary Prevention
LDL Cholesterol
Aspirin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Evaluation of the National Cholesterol Education Program Adult Treatment Panel III Algorithm for Selecting Candidates for Statin Therapy : Insights from the A to Z Trial. / de Lemos, James A; Wiviott, Stephen D.; Murphy, Sabina A.; Blazing, Michael A.; Lewis, Eldrin F.; Califf, Robert M.; Pfeffer, Marc A.; Braunwald, Eugene.

In: American Journal of Cardiology, Vol. 98, No. 6, 08.09.2006, p. 739-742.

Research output: Contribution to journalArticle

de Lemos, James A ; Wiviott, Stephen D. ; Murphy, Sabina A. ; Blazing, Michael A. ; Lewis, Eldrin F. ; Califf, Robert M. ; Pfeffer, Marc A. ; Braunwald, Eugene. / Evaluation of the National Cholesterol Education Program Adult Treatment Panel III Algorithm for Selecting Candidates for Statin Therapy : Insights from the A to Z Trial. In: American Journal of Cardiology. 2006 ; Vol. 98, No. 6. pp. 739-742.
@article{10acbf04877c427ca7e4a4aab0c30c81,
title = "Evaluation of the National Cholesterol Education Program Adult Treatment Panel III Algorithm for Selecting Candidates for Statin Therapy: Insights from the A to Z Trial",
abstract = "The National Cholesterol Education Program Adult Treatment Panel III recommends an algorithm to integrate iterative risk-stratification information with low-density lipoprotein (LDL) cholesterol levels to identify candidates for statin therapy. We used the Aggrastat to Zocor (A to Z) trial, in which all patients presented with an acute coronary syndrome (ACS) event in the absence of previous statin therapy, to evaluate the performance of this algorithm. Of 1,750 patients with ACS included in this analysis, 1,126 (64{\%}) had an indication for statin therapy before enrollment and 624 (36{\%}) did not have a statin indication before enrollment. We estimate that initiating statin therapy at moderate dosages (decreasing LDL by 1 mmol/L) according to the National Cholesterol Education Program Adult Treatment Panel III guidelines would have prevented approximately 15{\%} of the ACS events leading to enrollment in the A to Z trial, whereas more intensive statin therapy (decreasing LDL by 1.5 mmol/L) would have prevented >21{\%} of events. Aspirin use before enrollment was reported in only 38{\%} of subjects with a statin indication. In conclusion, these observations represent missed opportunities for primary and secondary prevention and highlight the need for assessment of patient risk and better adherence to existing prevention guidelines.",
author = "{de Lemos}, {James A} and Wiviott, {Stephen D.} and Murphy, {Sabina A.} and Blazing, {Michael A.} and Lewis, {Eldrin F.} and Califf, {Robert M.} and Pfeffer, {Marc A.} and Eugene Braunwald",
year = "2006",
month = "9",
day = "8",
doi = "10.1016/j.amjcard.2006.03.060",
language = "English (US)",
volume = "98",
pages = "739--742",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Evaluation of the National Cholesterol Education Program Adult Treatment Panel III Algorithm for Selecting Candidates for Statin Therapy

T2 - Insights from the A to Z Trial

AU - de Lemos, James A

AU - Wiviott, Stephen D.

AU - Murphy, Sabina A.

AU - Blazing, Michael A.

AU - Lewis, Eldrin F.

AU - Califf, Robert M.

AU - Pfeffer, Marc A.

AU - Braunwald, Eugene

PY - 2006/9/8

Y1 - 2006/9/8

N2 - The National Cholesterol Education Program Adult Treatment Panel III recommends an algorithm to integrate iterative risk-stratification information with low-density lipoprotein (LDL) cholesterol levels to identify candidates for statin therapy. We used the Aggrastat to Zocor (A to Z) trial, in which all patients presented with an acute coronary syndrome (ACS) event in the absence of previous statin therapy, to evaluate the performance of this algorithm. Of 1,750 patients with ACS included in this analysis, 1,126 (64%) had an indication for statin therapy before enrollment and 624 (36%) did not have a statin indication before enrollment. We estimate that initiating statin therapy at moderate dosages (decreasing LDL by 1 mmol/L) according to the National Cholesterol Education Program Adult Treatment Panel III guidelines would have prevented approximately 15% of the ACS events leading to enrollment in the A to Z trial, whereas more intensive statin therapy (decreasing LDL by 1.5 mmol/L) would have prevented >21% of events. Aspirin use before enrollment was reported in only 38% of subjects with a statin indication. In conclusion, these observations represent missed opportunities for primary and secondary prevention and highlight the need for assessment of patient risk and better adherence to existing prevention guidelines.

AB - The National Cholesterol Education Program Adult Treatment Panel III recommends an algorithm to integrate iterative risk-stratification information with low-density lipoprotein (LDL) cholesterol levels to identify candidates for statin therapy. We used the Aggrastat to Zocor (A to Z) trial, in which all patients presented with an acute coronary syndrome (ACS) event in the absence of previous statin therapy, to evaluate the performance of this algorithm. Of 1,750 patients with ACS included in this analysis, 1,126 (64%) had an indication for statin therapy before enrollment and 624 (36%) did not have a statin indication before enrollment. We estimate that initiating statin therapy at moderate dosages (decreasing LDL by 1 mmol/L) according to the National Cholesterol Education Program Adult Treatment Panel III guidelines would have prevented approximately 15% of the ACS events leading to enrollment in the A to Z trial, whereas more intensive statin therapy (decreasing LDL by 1.5 mmol/L) would have prevented >21% of events. Aspirin use before enrollment was reported in only 38% of subjects with a statin indication. In conclusion, these observations represent missed opportunities for primary and secondary prevention and highlight the need for assessment of patient risk and better adherence to existing prevention guidelines.

UR - http://www.scopus.com/inward/record.url?scp=33748058150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748058150&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.03.060

DO - 10.1016/j.amjcard.2006.03.060

M3 - Article

C2 - 16950174

AN - SCOPUS:33748058150

VL - 98

SP - 739

EP - 742

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -